{"entity":{"type":"insider","cik":"0001698823","url":"/insider/0001698823","json_url":"/insider/0001698823.json","name":"FHM LIFE SCIENCES VIII, L.L.C.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":8,"n_filings":8,"first":"2018-06-26","last":"2023-10-26","span_basis":"filed_date"},"name_variants":[{"name":"FHM LIFE SCIENCES VIII, L.L.C.","source":"filing","n_filings":8,"first_seen":"2018-06-26","last_seen":"2023-10-26"}],"transactions":[{"id":8156001,"accession":"0001209191-23-053662","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-053662","line_url":"/filing/0001209191-23-053662#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"Frazier Life Sciences VIII, L.P.; Topper James N; FHM LIFE SCIENCES VIII, L.P.; Heron Patrick J; FHM LIFE SCIENCES VIII, L.L.C.","owner_display_name":"Frazier Life Sciences VIII, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":80000.0,"shares_display":"80,000","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":200000.0,"total_display":"200,000.00","total_whole":"200,000","shares_owned_after":8764232.0,"shares_owned_after_display":"8,764,232","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-10-24","filed_date":"2023-10-26","scope":"insider"},{"id":6612968,"accession":"0001209191-22-045014","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-045014","line_url":"/filing/0001209191-22-045014#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"Frazier Life Sciences VIII, L.P.; FHM LIFE SCIENCES VIII, L.L.C.; FHM LIFE SCIENCES VIII, L.P.; Heron Patrick J; Topper James N","owner_display_name":"Frazier Life Sciences VIII, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":8684232.0,"shares_owned_after_display":"8,684,232","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-05","filed_date":"2022-08-09","scope":"insider"},{"id":6918554,"accession":"0001209191-22-009821","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-009821","line_url":"/filing/0001209191-22-009821#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"ALPINE IMMUNE SCIENCES, INC.","issuer_ticker":"ALPN","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"Topper James N; Frazier Life Sciences VIII, L.P.; Heron Patrick J; FHM LIFE SCIENCES VIII, L.P.; FHM LIFE SCIENCES VIII, L.L.C.","owner_display_name":"Topper James N","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":112665.0,"shares_display":"112,665","price_per_share":7.1006,"price_display":"7.10","price_state":"stated","total_value":799989.099,"total_display":"799,989.10","total_whole":"799,989","shares_owned_after":1484115.0,"shares_owned_after_display":"1,484,115","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-11","filed_date":"2022-02-15","scope":"insider"},{"id":2090194,"accession":"0001209191-20-007100","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-007100","line_url":"/filing/0001209191-20-007100#line-4","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"FHM LIFE SCIENCES VIII, L.P.; Topper James N; FHM LIFE SCIENCES VIII, L.L.C.; Frazier Life Sciences VIII, L.P.","owner_display_name":"FHM LIFE SCIENCES VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":8500000.0,"total_display":"8,500,000.00","total_whole":"8,500,000","shares_owned_after":10542790.0,"shares_owned_after_display":"10,542,790","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-04","filed_date":"2020-02-06","scope":"insider"},{"id":2576701,"accession":"0001209191-20-003162","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-003162","line_url":"/filing/0001209191-20-003162#line-1","is_derivative":false,"issuer_cik":"0001341382","issuer_name":"Entasis Therapeutics Holdings Inc.","issuer_ticker":"ETTX","issuer_name_source":null,"issuer_url":"/issuer/0001341382","owner_cik":null,"owner_name":"Heron Patrick J; Frazier Life Sciences VIII, L.P.; FHM LIFE SCIENCES VIII, L.L.C.; Topper James N; FHM LIFE SCIENCES VIII, L.P.","owner_display_name":"Heron Patrick J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":5.0002,"price_display":"5.00","price_state":"stated","total_value":250010.0,"total_display":"250,010.00","total_whole":"250,010","shares_owned_after":1299953.0,"shares_owned_after_display":"1,299,953","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-01-09","filed_date":"2020-01-13","scope":"insider"},{"id":8116928,"accession":"0001209191-19-004783","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-004783","line_url":"/filing/0001209191-19-004783#line-1","is_derivative":false,"issuer_cik":"0001365617","issuer_name":"ALPINE IMMUNE SCIENCES, INC.","issuer_ticker":"ALPN","issuer_name_source":null,"issuer_url":"/issuer/0001365617","owner_cik":null,"owner_name":"FHM LIFE SCIENCES VIII, L.L.C.; FHM LIFE SCIENCES VIII, L.P.; Frazier Life Sciences VIII, L.P.; Heron Patrick J","owner_display_name":"FHM LIFE SCIENCES VIII, L.L.C.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":372439.0,"shares_display":"372,439","price_per_share":5.37,"price_display":"5.37","price_state":"stated","total_value":1999997.43,"total_display":"1,999,997.43","total_whole":"1,999,997","shares_owned_after":2571450.0,"shares_owned_after_display":"2,571,450","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-18","filed_date":"2019-01-22","scope":"insider"},{"id":6047974,"accession":"0001209191-18-053535","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-053535","line_url":"/filing/0001209191-18-053535#line-4","is_derivative":false,"issuer_cik":"0001365617","issuer_name":"Entasis Therapeutics Holdings Inc.","issuer_ticker":"ETTX","issuer_name_source":null,"issuer_url":"/issuer/0001365617","owner_cik":null,"owner_name":"Heron Patrick J; FHM LIFE SCIENCES VIII, L.P.; Frazier Life Sciences VIII, L.P.; FHM LIFE SCIENCES VIII, L.L.C.","owner_display_name":"Heron Patrick J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":375887.0,"shares_display":"375,887","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":5638305.0,"total_display":"5,638,305.00","total_whole":"5,638,305","shares_owned_after":1349953.0,"shares_owned_after_display":"1,349,953","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-09-28","filed_date":"2018-10-02","scope":"insider"},{"id":6183637,"accession":"0001104659-18-042315","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-18-042315","line_url":"/filing/0001104659-18-042315#line-4","is_derivative":false,"issuer_cik":"0001365617","issuer_name":"Aptinyx Inc.","issuer_ticker":"APTX","issuer_name_source":null,"issuer_url":"/issuer/0001365617","owner_cik":null,"owner_name":"Frazier Life Sciences VIII, L.P.; FHM LIFE SCIENCES VIII, L.L.C.; Heron Patrick J; FHM LIFE SCIENCES VIII, L.P.","owner_display_name":"Frazier Life Sciences VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":2400000.0,"total_display":"2,400,000.00","total_whole":"2,400,000","shares_owned_after":3190079.0,"shares_owned_after_display":"3,190,079","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-25","filed_date":"2018-06-26","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001787306","name":"Arcutis Biotherapeutics, Inc.","url":"/issuer/0001787306","role":"Ten percent owner","n_filings":3,"first_seen":"2020-02-06","last_seen":"2023-10-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001626199","name":"ALPINE IMMUNE SCIENCES, INC.","url":"/issuer/0001626199","role":"Ten percent owner","n_filings":2,"first_seen":"2019-01-22","last_seen":"2022-02-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001724344","name":"Entasis Therapeutics Holdings Inc.","url":"/issuer/0001724344","role":"Ten percent owner","n_filings":2,"first_seen":"2018-10-02","last_seen":"2020-01-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001674365","name":"Aptinyx Inc.","url":"/issuer/0001674365","role":"Ten percent owner","n_filings":1,"first_seen":"2018-06-26","last_seen":"2018-06-26"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001698823","retrieved_at":"2026-08-23T05:47:29+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}